Updates O O O O
[ O O O O
Biomedical O O O O
Research O O O O
and O O O O
Therapy O O O O
receives O O O O
its O O O O
first O O O O
impact O O O O
factor O O O O
of O O O O
0.8 O O O O
(Q3) O O O O
](http://bmrat.org/index.php/BMRAT/announcement/view/16) O O O O
We O O O O
are O O O O
pleased O O O O
to O O O O
share O O O O
that O O O O
Biomedical O O O O
Research O O O O
and O O O O
Therapy O O O O
(ISSN: O O O O
2198-4093) O O O O
has O O O O
received O O O O
its O O O O
first O O O O
Impact O O O O
Factor O O O O
of O O O O
0.8 O O O O
in O O O O
the O O O O
Journal O O O O
Citation O O O O
Reports O O O O
(Clarivate) O O O O
in O O O O
June O O O O
2023. O O O O
Biomedical O O O O
Research O O O O
and O O O O
Therapy O O O O
continues O O O O
to O O O O
be O O O O
indexed O O O O
in O O O O
the O O O O
Emerging O O O O
Sources O O O O
Citation O O O O
Index O O O O
(ESCI) O O O O
within O O O O
the O O O O
Web O O O O
of O O O O
Science O O O O
Core O O O O
Collection. O O O O
This O O O O
is O O O O
the O O O O
first O O O O
time O O O O
that O O O O
Clarivate O O O O
has O O O O
awarded O O O O
Impact O O O O
Factors O O O O
to O O O O
journals O O O O
outside O O O O
of O O O O
the O O O O
core O O O O
flagship O O O O
indices, O O O O
SCIE O O O O
and O O O O
SSCI, O O O O
creating O O O O
greater O O O O
transparency O O O O
around O O O O
the O O O O
citedness O O O O
of O O O O
ESCI-indexed O O O O
journals. O O O O
[More O O O O
Updates](/index.php/BMRAT/announcement) O O O O
latest O O O O
Aberrant O O O O
B-Marker O O O O
Expression O O O O
by O O O O
Saidin O O O O
N., O O O O
I., O O O O
S., O O O O
Zulkeflee O O O O
R., O O O O
H., O O O O
Abdullah O O O O
A., O O O O
H., O O O O
Hassan O O O O
M., O O O O
N., O O O O
Abdullah O O O O
M., O O O O
Akbar O O O O
N., O O O O
A., O O O O
N., O O O O
Noor O O O O
N. O O O O
H. O O O O
M. O O O O
Summary: O O O O
Acute O O O O
myeloid O O O O
leukemia O O O O
(AML) O O O O
with O O O O
t(8;21)(q22;q22) O O O O
is O O O O
a O O O O
frequently O O O O
encountered O O O O
subtype O O O O
of O O O O
AML O O O O
with O O O O
recurrent O O O O
genetic O O O O
abnormalities, O O O O
found O O O O
in O O O O
approximately O O O O
1-5% O O O O
of O O O O
AML O O O O
cases. O O O O
Here, O O O O
we O O O O
present O O O O
cases O O O O
of O O O O
AML O O O O
with O O O O
t(8;21) O O O O
in O O O O
elderly O O O O
patients O O O O
with O O O O
aberrant O O O O
B-marker O O O O
expression O O O O
identified O O O O
at O O O O
our O O O O
institution, O O O O
including O O O O
their O O O O
clinical O O O O
outcomes O O O O
when O O O O
treated O O O O
with O O O O
hypomethylating O O O O
agents O O O O
and O O O O
BCL-2 O O O O
inhibitors. O O O O
[](http://bmrat.org/index.php/BMRAT/article/view/821) O O O O
The O O O O
Engineering O O O O
Biology O O O O
Problems O O O O
Book: O O O O
Bridging O O O O
the O O O O
gap O O O O
between O O O O
biomedicine O O O O
and O O O O
engineering O O O O
by O O O O
Klabukov O O O O
I.,. O O O O
Baranovskii O O O O
D. O O O O
Summary: O O O O
Progress O O O O
in O O O O
the O O O O
biological O O O O
sciences O O O O
requires O O O O
advanced O O O O
approaches O O O O
to O O O O
biological O O O O
education. O O O O
The O O O O
current O O O O
well-established O O O O
paradigm O O O O
rarely O O O O
uses O O O O
engineering O O O O
design O O O O
to O O O O
solve O O O O
biological O O O O
problems. O O O O
Engineering Reason 4 O O
biology Reason 4 O O
is Reason 4 O O
a Reason 4 O O
novel Reason 4 O O
science Reason 4 O O
field Reason 4 O O
and Reason 4 O O
academic Reason 4 O O
discipline Reason 4 O O
that Reason 4 O O
focuses Reason 4 O O
on Reason 4 O O
the Reason 4 O O
engineering Reason 4 O O
of Reason 4 O O
living Reason 4 O O
objects Reason 4 O O
using Reason 4 O O
biological Reason 4 O O
techniques. Reason 4 O O
We Reason 4 O O
believe Reason 4 O O
that Reason 4 O O
the Reason 4 O O
integration Reason 4 O O
of Reason 4 O O
engineering Reason 4 O O
components Reason 4 O O
into Reason 4 O O
biological Reason 4 O O
education Reason 4 O O
together Reason 4 O O
with Reason 4 O O
a Reason 4 O O
wide Reason 4 O O
application Reason 4 O O
of Reason 4 O O
engineering Reason 4 O O
methods Reason 4 O O
can Reason 4 O O
provide Reason 4 O O
considerable Reason 4 O O
benefits Reason 4 O O
to Reason 4 O O
the Reason 4 O O
education Reason 4 O O
system. Reason 4 O O
We O O O O
developed O O O O
the O O O O
``Engineering O O O O
Biology O O O O
Problems O O O O
Book'' O O O O
to O O O O
bridge O O O O
the O O O O
gap O O O O
between O O O O
biology, O O O O
medicine, O O O O
and O O O O
engineering. O O O O
[](http://bmrat.org/index.php/BMRAT/article/view/828) O O O O
Case O O O O
series O O O O
report: O O O O
simultaneous O O O O
internal O O O O
fixation O O O O
of O O O O
multiple O O O O
fractures O O O O
by O O O O
Vo O O O O
T., O O O O
Nguyen O O O O
T., O O O O
H., O O O O
To O O O O
K., O O O O
Nguyen O O O O
L., O O O O
Nguyen O O O O
D., O O O O
Ha O O O O
D., O O O O
Ngo O O O O
V., O O O O
Doan O O O O
N., O O O O
Le O O O O
Q. O O O O
Summary: O O O O
Polytrauma O O O O
is O O O O
often O O O O
associated O O O O
with O O O O
a O O O O
high O O O O
mortality O O O O
rate O O O O
and O O O O
requires O O O O
intensive O O O O
management. O O O O
Although Reason 3 O O
several Reason 3 O O
cases Reason 3 O O
of Reason 3 O O
polytrauma Reason 3 O O
have Reason 3 O O
been Reason 3 O O
reported Reason 3 O O
as Reason 3 O O
being Reason 3 O O
related Reason 3 O O
to Reason 3 O O
thoracic Reason 3 O O
or Reason 3 O O
brain Reason 3 O O
injury, Reason 3 O O
there Reason 3 O O
are Reason 3 O O
few Reason 3 O O
reports Reason 3 O O
concerning Reason 3 O O
multiple Reason 3 O O
fractures. Reason 3 O O
[] Reason 3 O O
We Reason 3 O O
aimed Reason 3 O O
to Reason 3 O O
present Reason 3 O O
a Reason 3 O O
case Reason 3 O O
series Reason 3 O O
report Reason 3 O O
about Reason 3 O O
polytrauma Reason 3 O O
with Reason 3 O O
multiple Reason 3 O O
fractures, Reason 3 O O
highlighting Reason 3 O O
several Reason 3 O O
clinical Reason 3 O O
importance Reason 3 O O
and Reason 3 O O
management Reason 3 O O
strategies. Reason 3 O O
[](http://bmrat.org/index.php/BMRAT/article/view/820) Reason 3 O O
Plasmablastic Reason 3 O O
transformation Reason 3 O O
of Reason 3 O O
multiple Reason 3 O O
myeloma Reason 3 O O
post-autologous Reason 3 O O
hematopoietic Reason 3 O O
stem Reason 3 O O
cell Reason 3 O O
transplant Reason 3 O O
by Reason 3 O O
Akbar Reason 3 O O
N., Reason 3 O O
A., Reason 3 O O
N., Reason 3 O O
Hassan Reason 3 O O
M., Reason 3 O O
Iberahim Reason 3 O O
S., Reason 3 O O
Saidin Reason 3 O O
N., Reason 3 O O
I., Reason 3 O O
S., Reason 3 O O
Roslan Reason 3 O O
W., Reason 3 O O
Halim Reason 3 O O
N., Reason 3 O O
A. Reason 3 O O
I, Reason 3 O O
A, Reason 3 O O
Abdullah Reason 3 O O
A., Reason 3 O O
D., Reason 3 O O
Hanafi Reason 3 O O
H., Reason 3 O O
H., Reason 3 O O
W., Reason 3 O O
Shukri Reason 3 O O
N., Reason 3 O O
D., Reason 3 O O
M., Reason 3 O O
Adzahar Reason 3 O O
S. Reason 3 O O
Summary: Reason 3 O O
The Reason 3 O O
present Reason 3 O O
case Reason 3 O O
report Reason 3 O O
describes Reason 3 O O
the Reason 3 O O
uncommon Reason 3 O O
and Reason 3 O O
adverse Reason 3 O O
plasmablastic Reason 3 O O
transformation Reason 3 O O
of Reason 3 O O
multiple Reason 3 O O
myeloma Reason 3 O O
(MM) Reason 3 O O
following Reason 3 O O
autologous Reason 3 O O
hematopoietic Reason 3 O O
stem Reason 3 O O
cell Reason 3 O O
transplantation. Reason 3 O O
To Reason 3 O O
the Reason 3 O O
best Reason 3 O O
of Reason 3 O O
our Reason 3 O O
knowledge, Reason 3 O O
this Reason 3 O O
is Reason 3 O O
the Reason 3 O O
first Reason 3 O O
case Reason 3 O O
of Reason 3 O O
plasmablastic Reason 3 O O
myeloma Reason 3 O O
(PBM) Reason 3 O O
after Reason 3 O O
an Reason 3 O O
autologous Reason 3 O O
hematopoietic Reason 3 O O
transplant Reason 3 O O
to Reason 3 O O
be Reason 3 O O
reported Reason 3 O O
in Reason 3 O O
Malaysia. Reason 3 O O
A Reason 3 O O
41-year-old Reason 3 O O
man Reason 3 O O
initially Reason 3 O O
diagnosed Reason 3 O O
with Reason 3 O O
MM Reason 3 O O
IgG Reason 3 O O
kappa Reason 3 O O
reported Reason 3 O O
lower Reason 3 O O
back Reason 3 O O
pain Reason 3 O O
symptoms Reason 3 O O
for Reason 3 O O
a Reason 3 O O
year, Reason 3 O O
along Reason 3 O O
with Reason 3 O O
other Reason 3 O O
associated Reason 3 O O
symptoms. Reason 3 O O
After Reason 4 O O
receiving Reason 4 O O
several Reason 4 O O
lines Reason 4 O O
of Reason 4 O O
chemotherapy, Reason 4 O O
the Reason 4 O O
patient Reason 4 O O
displayed Reason 4 O O
a Reason 4 O O
partial Reason 4 O O
response Reason 4 O O
(PR), Reason 4 O O
and Reason 4 O O
an Reason 4 O O
autologous Reason 4 O O
stem Reason 4 O O
cell Reason 4 O O
transplant Reason 4 O O
(ASCT) Reason 4 O O
was Reason 4 O O
subsequently Reason 4 O O
performed. Reason 4 O O
Two Reason 4 O O
months Reason 4 O O
after Reason 4 O O
the Reason 4 O O
transplant, Reason 4 O O
the Reason 4 O O
patient Reason 4 O O
showed Reason 4 O O
signs Reason 4 O O
of Reason 4 O O
anemia, Reason 4 O O
with Reason 4 O O
a Reason 4 O O
hemoglobin Reason 4 O O
level Reason 4 O O
of Reason 4 O O
8.0 Reason 4 O O
g/dL. Reason 4 O O
A Reason 4 O O
peripheral Reason 4 O O
blood Reason 4 O O
film Reason 4 O O
revealed Reason 4 O O
the Reason 4 O O
presence Reason 4 O O
of Reason 4 O O
a Reason 4 O O
leucoerythroblastic Reason 4 O O
blood Reason 4 O O
film Reason 4 O O
with Reason 4 O O
normocytic Reason 4 O O
normochromic Reason 4 O O
red Reason 4 O O
blood Reason 4 O O
cells Reason 4 O O
and Reason 4 O O
rouleaux Reason 4 O O
formation Reason 4 O O
but Reason 4 O O
no Reason 4 O O
apparent Reason 4 O O
plasma Reason 4 O O
cells. Reason 4 O O
The Reason 4 O O
main Reason 4 O O
infiltrating Reason 4 O O
cells Reason 4 O O
in Reason 4 O O
the Reason 4 O O
bone Reason 4 O O
marrow Reason 4 O O
aspirate Reason 4 O O
(BMA) Reason 4 O O
and Reason 4 O O
trephine Reason 4 O O
biopsy Reason 4 O O
were Reason 4 O O
plasmablasts Reason 4 O O
with Reason 4 O O
kappa Reason 4 O O
light Reason 4 O O
chain Reason 4 O O
restriction. Reason 4 O O
An Reason 4 O O
increase Reason 4 O O
in Reason 4 O O
serum Reason 4 O O
kappa Reason 4 O O
free Reason 4 O O
light Reason 4 O O
chain Reason 4 O O
(FLC), Reason 4 O O
serum Reason 4 O O
lambda Reason 4 O O
FLC, Reason 4 O O
and Reason 4 O O
a Reason 4 O O
low Reason 4 O O
albumin/globulin Reason 4 O O
(A/G) Reason 4 O O
ratio Reason 4 O O
were Reason 4 O O
observed. Reason 4 O O
In Reason 4 O O
addition, Reason 4 O O
serum Reason 4 O O
protein Reason 4 O O
electrophoresis Reason 4 O O
showed Reason 4 O O
an Reason 4 O O
IgG Reason 4 O O
kappa Reason 4 O O
paraprotein Reason 4 O O
band Reason 4 O O
in Reason 4 O O
the Reason 4 O O
gamma Reason 4 O O
region. Reason 4 O O
Post-ASCT, Reason 4 O O
the Reason 4 O O
disease Reason 4 O O
transformed Reason 4 O O
into Reason 4 O O
PBM, Reason 4 O O
which Reason 4 O O
conferred Reason 4 O O
a Reason 4 O O
poor Reason 4 O O
prognosis Reason 4 O O
on Reason 4 O O
thepatient Reason 4 O O
despite Reason 4 O O
his Reason 4 O O
post-transplant Reason 4 O O
status. Reason 4 O O
This Reason 4 O O
case Reason 4 O O
report Reason 4 O O
highlights Reason 4 O O
the Reason 4 O O
diagnostic Reason 4 O O
challenges Reason 4 O O
of Reason 4 O O
plasmablastic Reason 4 O O
transformation Reason 4 O O
in Reason 4 O O
MM. Reason 4 O O
Diagnosing Reason 4 O O
PBM Reason 4 O O
is Reason 4 O O
thus Reason 4 O O
crucial Reason 4 O O
for Reason 4 O O
the Reason 4 O O
prompt Reason 4 O O
and Reason 4 O O
proper Reason 4 O O
management Reason 4 O O
of Reason 4 O O
affected Reason 4 O O
patients. Reason 4 O O
Another Reason 4 O O
consideration Reason 4 O O
in Reason 4 O O
the Reason 4 O O
present Reason 4 O O
case Reason 4 O O
is Reason 4 O O
whether Reason 4 O O
the Reason 4 O O
transplant Reason 4 O O
procedure Reason 4 O O
itself Reason 4 O O
or Reason 4 O O
the Reason 4 O O
immunopathogenesis Reason 4 O O
that Reason 4 O O
took Reason 4 O O
place Reason 4 O O
after Reason 4 O O
the Reason 4 O O
ASCT Reason 4 O O
resulted Reason 4 O O
in Reason 4 O O
the Reason 4 O O
subsequent Reason 4 O O
transformation Reason 4 O O
into Reason 4 O O
PBM. Reason 4 O O
[](http://bmrat.org/index.php/BMRAT/article/view/823) Reason 4 O O
Comparison Reason 4 O O
of Reason 4 O O
cancer Reason 4 O O
stem Reason 4 O O
cell Reason 4 O O
enrichment Reason 4 O O
between Reason 4 O O
spheroids Reason 4 O O
derived Reason 4 O O
from Reason 4 O O
single-cell Reason 4 O O
and Reason 4 O O
multicellular Reason 4 O O
aggregate Reason 4 O O
cultures Reason 4 O O
by Reason 4 O O
Hairuddin Reason 4 O O
Yahaya Reason 4 O O
B., Reason 4 O O
Ibahim Reason 4 O O
M., Reason 4 O O
Verakumarasivam Reason 4 O O
A., Reason 4 O O
Choy Reason 4 O O
C., Reason 4 O O
M., Reason 4 O O
Rahim Reason 4 O O
N., Reason 4 O O
Dzulkarnain Reason 4 O O
S., Reason 4 O O
M., Reason 4 O O
Mansor Reason 4 O O
S. Reason 4 O O
Summary: Reason 4 O O
Cancer Reason 4 O O
stem Reason 4 O O
cells Reason 4 O O
(CSCs) Reason 4 O O
represent Reason 4 O O
a Reason 4 O O
distinct Reason 4 O O
group Reason 4 O O
of Reason 4 O O
cells Reason 4 O O
within Reason 4 O O
cancerous Reason 4 O O
tissue Reason 4 O O
that Reason 4 O O
possess Reason 4 O O
the Reason 4 O O
ability Reason 4 O O
to Reason 4 O O
initiate Reason 4 O O
tumorigenesis Reason 4 O O
and Reason 4 O O
exhibit Reason 4 O O
potency, Reason 4 O O
self-renewal, Reason 4 O O
and Reason 4 O O
drug Reason 4 O O
resistance. Reason 4 O O
The Reason 4 O O
study Reason 4 O O
of Reason 4 O O
CSCs Reason 4 O O
often Reason 4 O O
encounters Reason 4 O O
challenges Reason 4 O O
in Reason 4 O O
obtaining Reason 4 O O
these Reason 4 O O
cells Reason 4 O O
of Reason 4 O O
interest Reason 4 O O
or Reason 4 O O
generating Reason 4 O O
a Reason 4 O O
sufficient Reason 4 O O
quantity Reason 4 O O
for Reason 4 O O
downstream Reason 4 O O
analysis. Reason 4 O O
Nevertheless, Reason 4 O O
it Reason 4 O O
is Reason 4 O O
feasible Reason 4 O O
to Reason 4 O O
enrich Reason 4 O O
CSCs Reason 4 O O
in Reason 4 O O
vitro Reason 4 O O
by Reason 4 O O
subjecting Reason 4 O O
them Reason 4 O O
to Reason 4 O O
conditions Reason 4 O O
that Reason 4 O O
stimulate Reason 4 O O
their Reason 4 O O
CSC Reason 4 O O
properties, Reason 4 O O
such Reason 4 O O
as Reason 4 O O
prolonged Reason 4 O O
exposure Reason 4 O O
to Reason 4 O O
drugs Reason 4 O O
or Reason 4 O O
radiation, Reason 4 O O
or Reason 4 O O
by Reason 4 O O
promoting Reason 4 O O
their Reason 4 O O
self-renewal Reason 4 O O
capability Reason 4 O O
through Reason 4 O O
spheroid Reason 4 O O
culture. Reason 4 O O
Spheroids Reason 4 O O
are Reason 4 O O
a Reason 4 O O
specific Reason 4 O O
type Reason 4 O O
of Reason 4 O O
cell Reason 4 O O
culture Reason 4 O O
that Reason 4 O O
organizes Reason 4 O O
cells Reason 4 O O
into Reason 4 O O
a Reason 4 O O
three-dimensional Reason 4 O O
structure, Reason 4 O O
closely Reason 4 O O
mimicking Reason 4 O O
the Reason 4 O O
in Reason 4 O O
vivo Reason 4 O O
environment. Reason 4 O O
These Reason 4 O O
spheroids Reason 4 O O
consist Reason 4 O O
of Reason 4 O O
a Reason 4 O O
heterogeneous Reason 4 O O
cell Reason 4 O O
population, Reason 4 O O
including Reason 4 O O
CSCs Reason 4 O O
or Reason 4 O O
tumor-propagating Reason 4 O O
cells Reason 4 O O
responsible Reason 4 O O
for Reason 4 O O
tumor Reason 4 O O
growth Reason 4 O O
and Reason 4 O O
maintenance. Reason 4 O O
In Reason 4 O O
our Reason 4 O O
study, Reason 4 O O
we Reason 4 O O
cultured Reason 4 O O
spheroids Reason 4 O O
derived Reason 4 O O
from Reason 4 O O
single Reason 4 O O
cells Reason 4 O O
as Reason 4 O O
well Reason 4 O O
as Reason 4 O O
multicellular Reason 4 O O
aggregates Reason 4 O O
to Reason 4 O O
enrich Reason 4 O O
CSCs Reason 4 O O
based Reason 4 O O
on Reason 4 O O
their Reason 4 O O
self-renewal Reason 4 O O
capability Reason 4 O O
and Reason 4 O O
the Reason 4 O O
structural Reason 4 O O
organization Reason 4 O O
provided Reason 4 O O
by Reason 4 O O
the Reason 4 O O
three-dimensional Reason 4 O O
context. Reason 4 O O
[](http://bmrat.org/index.php/BMRAT/article/view/825) Reason 4 O O
Correlation Reason 4 O O
between Reason 4 O O
Angiotensin Reason 4 O O
Converting Reason 4 O O
Enzyme Reason 4 O O
Insertion-Deletion Reason 4 O O
Polymorphisms Reason 4 O O
and Reason 4 O O
Cardiovascular Reason 4 O O
Risk Reason 4 O O
Factor Reason 4 O O
Determinants Reason 4 O O
in Reason 4 O O
Urban Reason 4 O O
and Reason 4 O O
Rural Reason 4 O O
Populations Reason 4 O O
by Reason 4 O O
Ismail Reason 4 O O
I., Reason 4 O O
Basri Reason 4 O O
M., Reason 4 O O
Mustafa Reason 4 O O
M., Reason 4 O O
Nukhotimah Reason 4 O O
A. Reason 4 O O
Summary: Reason 4 O O
The Reason 4 O O
angiotensin Reason 4 O O
insertion-deletion Reason 4 O O
(ACE Reason 4 O O
located Reason 4 O O
on Reason 4 O O
chromosome Reason 4 O O
17q23 Reason 4 O O
(287 Reason 4 O O
bp Reason 4 O O
in Reason 4 O O
intron Reason 4 O O
16) Reason 4 O O
is Reason 4 O O
associated Reason 4 O O
with Reason 4 O O
cardiovascular Reason 4 O O
risk Reason 4 O O
factors Reason 4 O O
(CRFs), Reason 4 O O
but Reason 4 O O
results Reason 4 O O
vary Reason 4 O O
among Reason 4 O O
populations, Reason 4 O O
which Reason 4 O O
is Reason 4 O O
thought Reason 4 O O
to Reason 4 O O
be Reason 4 O O
the Reason 4 O O
cause Reason 4 O O
of Reason 4 O O
ethnic Reason 4 O O
differences. Reason 4 O O
This Reason 4 O O
study Reason 4 O O
explored Reason 4 O O
the Reason 4 O O
role Reason 4 O O
of Reason 4 O O
the Reason 4 O O
ACE Reason 4 O O
I/D Reason 4 O O
polymorphism Reason 4 O O
and Reason 4 O O
its Reason 4 O O
correlation Reason 4 O O
with Reason 4 O O
CRF Reason 4 O O
determinants Reason 4 O O
among Reason 4 O O
urban Reason 4 O O
and Reason 4 O O
rural Reason 4 O O
groups. Reason 4 O O
[](http://bmrat.org/index.php/BMRAT/article/view/826) Reason 4 O O
Association Reason 4 O O
Between Reason 4 O O
Interleukin Reason 4 O O
6 Reason 4 O O
Immunohistochemical Reason 4 O O
and Reason 4 O O
Plasma Reason 4 O O
Levels Reason 4 O O
in Reason 4 O O
Invasive Reason 4 O O
Ductal Reason 4 O O
Carcinoma Reason 4 O O
Breast: Reason 4 O O
A Reason 4 O O
Cross-Sectional Reason 4 O O
Study Reason 4 O O
by Reason 4 O O
Girdhar Reason 4 O O
A., Reason 4 O O
Raju Reason 4 O O
K., Reason 4 O O
Prasad Reason 4 O O
K. Reason 4 O O
Summary: Reason 4 O O
Breast Reason 4 O O
carcinoma Reason 4 O O
(BC) Reason 4 O O
is Reason 4 O O
one Reason 4 O O
of Reason 4 O O
the Reason 4 O O
most Reason 4 O O
common Reason 4 O O
malignancies Reason 4 O O
in Reason 4 O O
women, Reason 4 O O
affecting Reason 4 O O
1 Reason 4 O O
in Reason 4 O O
8. Reason 4 O O
Interleukin Reason 4 O O
6 Reason 4 O O
(IL6) Reason 4 O O
is Reason 4 O O
a Reason 4 O O
proinflammatory Reason 4 O O
cytokine. Reason 4 O O
The Reason 4 O O
role Reason 4 O O
of Reason 4 O O
IL6 Reason 4 O O
pathways Reason 4 O O
in Reason 4 O O
breast Reason 4 O O
cancer Reason 4 O O
motivated Reason 4 O O
the Reason 4 O O
development Reason 4 O O
of Reason 4 O O
anti-IL6 Reason 4 O O
agents Reason 4 O O
or Reason 4 O O
monoclonal Reason 4 O O
antibodies, Reason 4 O O
which Reason 4 O O
inhibit Reason 4 O O
the Reason 4 O O
IL6/signal Reason 4 O O
transducer Reason 4 O O
and Reason 4 O O
activator Reason 4 O O
of Reason 4 O O
transcription Reason 4 O O
3 Reason 4 O O
(STAT3) Reason 4 O O
pathway. Reason 4 O O
This Reason 4 O O
study Reason 4 O O
aimed Reason 4 O O
to Reason 4 O O
determine Reason 4 O O
the Reason 4 O O
proportion Reason 4 O O
and Reason 4 O O
intensity Reason 4 O O
of Reason 4 O O
immunohistochemical Reason 4 O O
(IHC) Reason 4 O O
IL6 Reason 4 O O
expression Reason 4 O O
in Reason 4 O O
invasive Reason 4 O O
ductal Reason 4 O O
carcinoma Reason 4 O O
(IDC) Reason 4 O O
breast Reason 4 O O
tissue Reason 4 O O
sections Reason 4 O O
and Reason 4 O O
estimate Reason 4 O O
plasma Reason 4 O O
IL6 Reason 4 O O
levels Reason 4 O O
using Reason 4 O O
an Reason 4 O O
enzyme-linked Reason 4 O O
immunosorbent Reason 4 O O
assay Reason 4 O O
(ELISA) Reason 4 O O
in Reason 4 O O
the Reason 4 O O
same Reason 4 O O
patients Reason 4 O O
to Reason 4 O O
evaluate Reason 4 O O
the Reason 4 O O
association Reason 4 O O
between Reason 4 O O
IHC Reason 4 O O
and Reason 4 O O
plasma Reason 4 O O
IL6 Reason 4 O O
levels. Reason 4 O O
[](http://bmrat.org/index.php/BMRAT/article/view/827) Reason 4 O O
The Reason 4 O O
cytotoxic Reason 4 O O
effect Reason 4 O O
of Reason 4 O O
Vernonia Reason 4 O O
amygdalina Reason 4 O O
Del. Reason 4 O O
extract Reason 4 O O
on Reason 4 O O
myeloid Reason 4 O O
leukemia Reason 4 O O
cells Reason 4 O O
by Reason 4 O O
Quan Reason 4 O O
N., Reason 4 O O
Ly Reason 4 O O
B., Reason 4 O O
Chi Reason 4 O O
H. Reason 4 O O
Summary: Reason 4 O O
This Reason 4 O O
study Reason 4 O O
aimed Reason 4 O O
to Reason 4 O O
demonstrate Reason 4 O O
the Reason 4 O O
cytotoxic Reason 4 O O
effect Reason 4 O O
of Reason 4 O O
a Reason 4 O O
bitter Reason 4 O O
leaf Reason 4 O O
(Vernonia Reason 4 O O
amygdalina Reason 4 O O
Del.) Reason 4 O O
ethanol Reason 4 O O
extract Reason 4 O O
on Reason 4 O O
myeloid Reason 4 O O
leukemia Reason 4 O O
cells. Reason 4 O O
[](http://bmrat.org/index.php/BMRAT/article/view/819) Reason 4 O O
Genes Reason 4 O O
involved Reason 4 O O
in Reason 4 O O
premature Reason 4 O O
aging Reason 4 O O
and Reason 4 O O
their Reason 4 O O
association Reason 4 O O
with Reason 4 O O
age-related Reason 4 O O
diseases: Reason 4 O O
A Reason 4 O O
mini Reason 4 O O
review Reason 4 O O
by Reason 4 O O
Agraharam Reason 4 O O
G., Reason 4 O O
Girigoswami Reason 4 O O
A., Reason 4 O O
Gowtham Reason 4 O O
P., Reason 4 O O
Girigoswami Reason 4 O O
K. Reason 4 O O
Summary: Reason 4 O O
Aging Reason 4 O O
is Reason 4 O O
an Reason 4 O O
irreversible Reason 4 O O
biological Reason 4 O O
process Reason 4 O O
observed Reason 4 O O
in Reason 4 O O
living Reason 4 O O
organisms, Reason 4 O O
with Reason 4 O O
each Reason 4 O O
cell Reason 4 O O
demonstrating Reason 4 O O
this Reason 4 O O
mechanism. Reason 4 O O
Age-related Reason 4 O O
decline Reason 4 O O
in Reason 4 O O
cellular Reason 4 O O
integrity Reason 4 O O
due Reason 4 O O
to Reason 4 O O
various Reason 4 O O
endogenous Reason 4 O O
and Reason 4 O O
exogenous Reason 4 O O
factors Reason 4 O O
and Reason 4 O O
mechanisms Reason 4 O O
contributes Reason 4 O O
to Reason 4 O O
several Reason 4 O O
diseases Reason 4 O O
based Reason 4 O O
on Reason 4 O O
the Reason 4 O O
site Reason 4 O O
or Reason 4 O O
location Reason 4 O O
of Reason 4 O O
the Reason 4 O O
decline. Reason 4 O O
Cardiovascular Reason 4 O O
diseases, Reason 4 O O
diabetes, Reason 4 O O
cancer, Reason 4 O O
osteoarthritis, Reason 4 O O
and Reason 4 O O
osteoporosis Reason 4 O O
are Reason 4 O O
some Reason 4 O O
examples Reason 4 O O
of Reason 4 O O
age-related Reason 4 O O
diseases. Reason 4 O O
Reports Reason 4 O O
suggest Reason 4 O O
several Reason 4 O O
premature Reason 4 O O
aging Reason 4 O O
genes Reason 4 O O
contribute Reason 4 O O
to Reason 4 O O
the Reason 4 O O
genetic, Reason 4 O O
pathological, Reason 4 O O
and Reason 4 O O
physiological Reason 4 O O
variations Reason 4 O O
of Reason 4 O O
an Reason 4 O O
organism Reason 4 O O
that Reason 4 O O
is Reason 4 O O
similar Reason 4 O O
to Reason 4 O O
the Reason 4 O O
aging Reason 4 O O
organism Reason 4 O O
and Reason 4 O O
might Reason 4 O O
explain Reason 4 O O
the Reason 4 O O
genes Reason 4 O O
associated Reason 4 O O
with Reason 4 O O
aging. Reason 4 O O
We Reason 4 O O
used Reason 4 O O
the Reason 4 O O
DisGeNET Reason 4 O O
web Reason 4 O O
tool Reason 4 O O
to Reason 4 O O
retrieve Reason 4 O O
genes Reason 4 O O
associated Reason 4 O O
with Reason 4 O O
premature Reason 4 O O
aging. Reason 4 O O
We Reason 4 O O
used Reason 4 O O
the Reason 4 O O
Cytoscape Reason 4 O O
software Reason 4 O O
and Reason 4 O O
STRING Reason 4 O O
online Reason 4 O O
tool Reason 4 O O
for Reason 4 O O
identifying Reason 4 O O
protein-protein Reason 4 O O
networks. Reason 4 O O
We Reason 4 O O
retrieved Reason 4 O O
136 Reason 4 O O
genes Reason 4 O O
associated Reason 4 O O
with Reason 4 O O
premature Reason 4 O O
aging Reason 4 O O
and Reason 4 O O
compared Reason 4 O O
their Reason 4 O O
association Reason 4 O O
with Reason 4 O O
age-related Reason 4 O O
diseases. Reason 4 O O
Many Reason 4 O O
of Reason 4 O O
these Reason 4 O O
premature Reason 4 O O
agingassociated Reason 4 O O
genes Reason 4 O O
were Reason 4 O O
associated Reason 4 O O
with Reason 4 O O
cardiovascular Reason 4 O O
disease Reason 4 O O
(56), Reason 4 O O
diabetes Reason 4 O O
type Reason 4 O O
II Reason 4 O O
(71), Reason 4 O O
Parkinson's Reason 4 O O
disease Reason 4 O O
(54), Reason 4 O O
Alzheimer's Reason 4 O O
disease Reason 4 O O
(86), Reason 4 O O
prostate Reason 4 O O
cancer Reason 4 O O
progression Reason 4 O O
(23), Reason 4 O O
osteoarthritis Reason 4 O O
(15), Reason 4 O O
osteoporosis Reason 4 O O
(53), Reason 4 O O
age-related Reason 4 O O
macular Reason 4 O O
degeneration Reason 4 O O
(35), Reason 4 O O
cataracts Reason 4 O O
(44), Reason 4 O O
and Reason 4 O O
sensorineural Reason 4 O O
hearing Reason 4 O O
loss Reason 4 O O
(26). Reason 4 O O
This O O O O
article O O O O
provides O O O O
a O O O O
brief O O O O
review O O O O
of O O O O
some O O O O
of O O O O
the O O O O
genes O O O O
involved O O O O
in O O O O
premature O O O O
aging. O O O O
[](http://bmrat.org/index.php/BMRAT/article/view/818) O O O O
Structural O O O O
genomics O O O O
and O O O O
immunoinformatics O O O O
analyses O O O O
of O O O O
non-structural O O O O
protein O O O O
6 O O O O
(NSP6) O O O O
and O O O O
its O O O O
probable O O O O
role O O O O
in O O O O
autophagy O O O O
by O O O O
Yashvardhini O O O O
N., O O O O
Jha O O O O
D., O O O O
Khan O O O O
P., O O O O
Kumar O O O O
A., O O O O
Pranay O O O O
K. O O O O
Summary: O O O O
Autophagy O O O O
is O O O O
a O O O O
natural O O O O
cellular O O O O
mechanism O O O O
in O O O O
which O O O O
cellular O O O O
components O O O O
such O O O O
as O O O O
long-lived O O O O
proteins O O O O
and O O O O
damaged O O O O
organelles O O O O
are O O O O
degraded O O O O
in O O O O
response O O O O
to O O O O
starvation O O O O
by O O O O
forming O O O O
autophagosomes. O O O O
Viruses O O O O
activate O O O O
the O O O O
autophagy O O O O
process, O O O O
which O O O O
generates O O O O
innate O O O O
immune O O O O
protection O O O O
in O O O O
the O O O O
host O O O O
against O O O O
infection. O O O O
While O O O O
the O O O O
actual O O O O
molecular O O O O
mechanism O O O O
of O O O O
this O O O O
contagious O O O O
viral O O O O
infection O O O O
remains O O O O
unknown, O O O O
studies O O O O
on O O O O
some O O O O
other O O O O
betacoronavirus O O O O
show O O O O
that O O O O
their O O O O
infection O O O O
of O O O O
host O O O O
cells O O O O
inhibits O O O O
the O O O O
autophagy O O O O
process, O O O O
resulting O O O O
in O O O O
autophagosome O O O O
accumulation O O O O
inside O O O O
the O O O O
cells. O O O O
Non-structural Reason 3 O O
protein Reason 3 O O
6 Reason 3 O O
(NSP6) Reason 3 O O
is Reason 3 O O
crucial Reason 3 O O
in Reason 3 O O
blocking Reason 3 O O
autophagosomes/autolysosome Reason 3 O O
vesicle Reason 3 O O
formation, Reason 3 O O
which Reason 3 O O
are Reason 3 O O
more Reason 3 O O
numerous Reason 3 O O
and Reason 3 O O
smaller Reason 3 O O
than Reason 3 O O
autophagosomes Reason 3 O O
formed Reason 3 O O
upon Reason 3 O O
starvation. Reason 3 O O
Because O O O O
of O O O O
its O O O O
vital O O O O
role O O O O
in O O O O
autophagy, O O O O
NSP6 O O O O
can O O O O
be O O O O
used O O O O
as O O O O
an O O O O
effective O O O O
drug O O O O
target O O O O
to O O O O
combat O O O O
severe O O O O
acute O O O O
respiratory O O O O
syndrome O O O O
coronavirus O O O O
2 O O O O
(SARS-CoV-2) O O O O
infections. O O O O
Therefore, O O O O
this O O O O
study O O O O
aims O O O O
to O O O O
detect O O O O
the O O O O
mutations O O O O
in O O O O
the O O O O
NSP6 O O O O
of O O O O
Indian O O O O
isolates O O O O
compared O O O O
to O O O O
Wuhan-type O O O O
isolates. O O O O
The O O O O
NSP6 O O O O
protein O O O O
of O O O O
Indiantype O O O O
SARS-CoV-2 O O O O
isolates O O O O
contained O O O O
654 O O O O
point O O O O
mutations. O O O O
Furthermore, O O O O
secondary O O O O
structure, O O O O
energy O O O O
change O O O O
upon O O O O
mutation, O O O O
physicochemical O O O O
properties, O O O O
and O O O O
hydropathy O O O O
index O O O O
of O O O O
wild O O O O
and O O O O
mutated O O O O
proteins O O O O
were O O O O
compared, O O O O
clearly O O O O
showing O O O O
that O O O O
mutations O O O O
altered O O O O
NSP6 O O O O
stability. O O O O
An O O O O
immunoinformatics O O O O
approach O O O O
was O O O O
also O O O O
attempted O O O O
to O O O O
identify O O O O
the O O O O
B-cell O O O O
and O O O O
interferon O O O O
(IFN)-inducing O O O O
epitopes O O O O
for O O O O
using O O O O
NSP6 O O O O
as O O O O
a O O O O
probable O O O O
vaccine O O O O
candidate. O O O O
Therefore, O O O O
this O O O O
study O O O O
explored O O O O
an O O O O
important O O O O
drug O O O O
target O O O O
(NSP6) O O O O
essential O O O O
for O O O O
autophagy O O O O
and O O O O
assembly O O O O
of O O O O
coronavirus O O O O
replicase O O O O
proteins. O O O O
[](http://bmrat.org/index.php/BMRAT/article/view/816) O O O O
Hepatocellular O O O O
adenoma O O O O
a O O O O
child: O O O O
a O O O O
case O O O O
report O O O O
by O O O O
Khai O O O O
T., O O O O
Phuong O O O O
T., O O O O
Hung O O O O
P., O O O O
Huy O O O O
L., O O O O
Khanh O O O O
Hepatocellular O O O O
adenoma O O O O
(HCA) O O O O
is O O O O
a O O O O
rare O O O O
noninvasive O O O O
adenoma O O O O
of O O O O
the O O O O
liver, O O O O
occasionally O O O O
observed O O O O
in O O O O
childbearing-aged O O O O
women O O O O
who O O O O
use O O O O
contraceptive O O O O
pills O O O O
(85% O O O O
of O O O O
which O O O O
contain O O O O
steroids) O O O O
and O O O O
is O O O O
infrequent O O O O
in O O O O
children. O O O O
HCA O O O O
can O O O O
cause O O O O
several O O O O
complications O O O O
such O O O O
as O O O O
hemorrhage O O O O
(20-25%) O O O O
or O O O O
proceed O O O O
to O O O O
malignancy O O O O
(4-10%), O O O O
especially O O O O
when O O O O
the O O O O
tumor O O O O
size O O O O
is O O O O
greater O O O O
than O O O O
5 O O O O
cm. O O O O
The O O O O
clinical O O O O
manifestation O O O O
of O O O O
HCA O O O O
is O O O O
variable, O O O O
from O O O O
asymptomatic O O O O
to O O O O
tumor O O O O
rupture. O O O O
Most Reason 3 O O
cases Reason 3 O O
admitted Reason 3 O O
to Reason 3 O O
hospitals Reason 3 O O
are Reason 3 O O
due Reason 3 O O
to Reason 3 O O
mild Reason 3 O O
atypical Reason 3 O O
abdominal Reason 3 O O
discomfort. Reason 3 O O
[] Reason 3 O O
HCA Reason 3 O O
is Reason 3 O O
classified Reason 3 O O
into Reason 3 O O
four Reason 3 O O
types, Reason 3 O O
based Reason 3 O O
on Reason 3 O O
molecular Reason 3 O O
behavior, Reason 3 O O
HNF-1a Reason 3 O O
inactive, Reason 3 O O
b Reason 3 O O
-catenin Reason 3 O O
activated, Reason 3 O O
inflammatory Reason 3 O O
HCA, Reason 3 O O
and Reason 3 O O
unclassified Reason 3 O O
HCA. Reason 3 O O
Among Reason 3 O O
them, Reason 3 O O
the Reason 3 O O
b Reason 3 O O
-catenin Reason 3 O O
activated Reason 3 O O
subgroup Reason 3 O O
carries Reason 3 O O
the Reason 3 O O
highest Reason 3 O O
risk Reason 3 O O
of Reason 3 O O
hemorrhage Reason 3 O O
and Reason 3 O O
malignant Reason 3 O O
transformation. Reason 3 O O
[](http://bmrat.org/index.php/BMRAT/article/view/817) Reason 3 O O
Cavitary Reason 3 O O
lesion Reason 3 O O
from Reason 3 O O
pulmonary Reason 3 O O
nocardiosis Reason 3 O O
in Reason 3 O O
non-immunocompromised Reason 3 O O
patients Reason 3 O O
with Reason 3 O O
chronic Reason 3 O O
lung Reason 3 O O
disease: Reason 3 O O
A Reason 3 O O
report Reason 3 O O
of Reason 3 O O
three Reason 3 O O
cases Reason 3 O O
by Reason 3 O O
Nguyen-Dang Reason 3 O O
K., Reason 3 O O
Le-Thuong Reason 3 O O
V., Reason 3 O O
Nguyen-Ho Reason 3 O O
L., Reason 3 O O
Tran-Ngoc Reason 3 O O
N. Reason 3 O O
Summary: Reason 3 O O
Pulmonary Reason 3 O O
nocardiosis Reason 3 O O
commonly Reason 3 O O
presents Reason 3 O O
with Reason 3 O O
respiratory Reason 3 O O
symptoms Reason 3 O O
resembling Reason 3 O O
those Reason 3 O O
observed Reason 3 O O
in Reason 3 O O
community-acquired Reason 3 O O
pneumonia Reason 3 O O
caused Reason 3 O O
by Reason 3 O O
other Reason 3 O O
agents. Reason 3 O O
Nocardia Reason 3 O O
was Reason 3 O O
previously Reason 3 O O
considered Reason 3 O O
to Reason 3 O O
primarily Reason 3 O O
affect Reason 3 O O
immunocompromised Reason 3 O O
populations, Reason 3 O O
particularly Reason 3 O O
transplant Reason 3 O O
patients. Reason 3 O O
[] Reason 3 O O
However, Reason 3 O O
recent Reason 3 O O
studies Reason 3 O O
have Reason 3 O O
indicated Reason 3 O O
a Reason 3 O O
rise Reason 3 O O
in Reason 3 O O
the Reason 3 O O
incidence Reason 3 O O
of Reason 3 O O
pulmonary Reason 3 O O
nocardiosis Reason 3 O O
among Reason 3 O O
non-immunocompromised Reason 3 O O
patients. Reason 3 O O
In Reason 3 O O
this Reason 3 O O
report, Reason 3 O O
we Reason 3 O O
present Reason 3 O O
the Reason 3 O O
cases Reason 3 O O
of Reason 3 O O
three Reason 3 O O
nonimmunocompromised Reason 3 O O
patients Reason 3 O O
with Reason 3 O O
pulmonary Reason 3 O O
nocardiosis Reason 3 O O
with Reason 3 O O
a Reason 3 O O
subacute Reason 3 O O
clinical Reason 3 O O
presentation Reason 3 O O
who Reason 3 O O
showed Reason 3 O O
cavitation Reason 3 O O
on Reason 3 O O
chest Reason 3 O O
computed Reason 3 O O
tomography. Reason 3 O O
Our Reason 3 O O
reports Reason 3 O O
emphasize Reason 3 O O
the Reason 3 O O
potential Reason 3 O O
diagnostic Reason 3 O O
clues Reason 3 O O
documented Reason 3 O O
in Reason 3 O O
the Reason 3 O O
literature Reason 3 O O
that Reason 3 O O
may Reason 3 O O
help Reason 3 O O
pulmonary Reason 3 O O
nocardiosis Reason 3 O O
diagnostic Reason 3 O O
investigations. Reason 3 O O
The Reason 3 O O
development Reason 3 O O
of Reason 3 O O
a Reason 3 O O
high Reason 3 O O
index Reason 3 O O
of Reason 3 O O
suspicion Reason 3 O O
for Reason 3 O O
pulmonary Reason 3 O O
nocardiosis Reason 3 O O
remains Reason 3 O O
crucial. Reason 3 O O
[](http://bmrat.org/index.php/BMRAT/article/view/815) Reason 3 O O
Mesenchymal Reason 3 O O
stem Reason 3 O O
cell Reason 3 O O
transplantation Reason 3 O O
for Reason 3 O O
infertility Reason 3 O O
treatment: Reason 3 O O
A Reason 3 O O
review Reason 3 O O
by Reason 3 O O
Mirfakhraie Reason 3 O O
R., Reason 3 O O
Lasemi Reason 3 O O
M., Reason 3 O O
Mehravar Reason 3 O O
M., Reason 3 O O
Halvachi Reason 3 O O
D., Reason 3 O O
Salimi Reason 3 O O
M., Reason 3 O O
Roshandel Reason 3 O O
E. Reason 3 O O
Summary: Reason 3 O O
Infertility Reason 3 O O
is Reason 3 O O
a Reason 3 O O
global Reason 3 O O
disorder Reason 3 O O
is Reason 3 O O
resulted Reason 3 O O
from Reason 3 O O
factors Reason 3 O O
related Reason 3 O O
to Reason 3 O O
men Reason 3 O O
or Reason 3 O O
women Reason 3 O O
and Reason 3 O O
affects Reason 3 O O
not Reason 3 O O
only Reason 3 O O
the Reason 3 O O
individual, Reason 3 O O
but Reason 3 O O
also Reason 3 O O
the Reason 3 O O
family Reason 3 O O
and Reason 3 O O
society. Reason 3 O O
Recently, Reason 3 O O
stem Reason 3 O O
cell-based Reason 3 O O
therapy, Reason 3 O O
known Reason 3 O O
as Reason 3 O O
regenerative Reason 3 O O
medicine, Reason 3 O O
uses Reason 3 O O
stem Reason 3 O O
cells Reason 3 O O
or Reason 3 O O
their Reason 3 O O
derivatives Reason 3 O O
to Reason 3 O O
treat Reason 3 O O
diseases, Reason 3 O O
promising Reason 3 O O
new Reason 3 O O
ways Reason 3 O O
to Reason 3 O O
treat Reason 3 O O
infertility. Reason 3 O O
Several Reason 3 O O
in Reason 3 O O
vitro Reason 3 O O
studies Reason 3 O O
as Reason 3 O O
well Reason 3 O O
as Reason 3 O O
studies Reason 3 O O
on Reason 3 O O
animal Reason 3 O O
models, Reason 3 O O
confirm Reason 3 O O
the Reason 3 O O
role Reason 3 O O
of Reason 3 O O
Mesenchymal Reason 3 O O
stem Reason 3 O O
cells Reason 3 O O
(MSC), Reason 3 O O
a Reason 3 O O
kind Reason 3 O O
of Reason 3 O O
multipotent Reason 3 O O
stem Reason 3 O O
cells, Reason 3 O O
in Reason 3 O O
the Reason 3 O O
recovery Reason 3 O O
of Reason 3 O O
folliculogenesis Reason 3 O O
and Reason 3 O O
spermatogenesis. Reason 3 O O
MSCs Reason 4 O O
play Reason 4 O O
the Reason 4 O O
role Reason 4 O O
of Reason 4 O O
therapeutic Reason 4 O O
effect Reason 4 O O
in Reason 4 O O
infertility Reason 4 O O
from Reason 4 O O
two Reason 4 O O
basic Reason 4 O O
aspects Reason 4 O O
including Reason 4 O O
regenerative Reason 4 O O
medicin Reason 4 O O
through Reason 4 O O
differentiation Reason 4 O O
and Reason 4 O O
paracrine Reason 4 O O
pathway Reason 4 O O
via Reason 4 O O
participating Reason 4 O O
in Reason 4 O O
cell Reason 4 O O
homing, Reason 4 O O
immune Reason 4 O O
regulation, Reason 4 O O
and Reason 4 O O
the Reason 4 O O
secretion Reason 4 O O
of Reason 4 O O
active Reason 4 O O
factors Reason 4 O O
and Reason 4 O O
exosomes. Reason 4 O O
Furthermore, Reason 4 O O
there Reason 4 O O
are Reason 4 O O
fewer Reason 4 O O
ethical Reason 4 O O
concerns Reason 4 O O
about Reason 4 O O
using Reason 4 O O
MSCs Reason 4 O O
compared Reason 4 O O
to Reason 4 O O
other Reason 4 O O
source Reason 4 O O
of Reason 4 O O
stem Reason 4 O O
cells Reason 4 O O
like Reason 4 O O
embryonic Reason 4 O O
stem Reason 4 O O
cells. Reason 4 O O
Here O O O O
we O O O O
discuss O O O O
therapeutic O O O O
approaches O O O O
of O O O O
different O O O O
sources O O O O
of O O O O
MSC O O O O
to O O O O
restore O O O O
fertility, O O O O
then O O O O
the O O O O
basic O O O O
aspects O O O O
related O O O O
to O O O O
their O O O O
paracrine O O O O
effects O O O O
will O O O O
be O O O O
described O O O O
in O O O O
detail. O O O O
[](http://bmrat.org/index.php/BMRAT/article/view/814) O O O O
An O O O O
analysis O O O O
of O O O O
the O O O O
impact O O O O
of O O O O
buthionine O O O O
sulfoximine O O O O
and O O O O
N-nitro-L-arginine O O O O
on O O O O
blood O O O O
pressure O O O O
by O O O O
Gungor O O O O
B., O O O O
S., O O O O
Silan O O O O
C., O O O O
Coskun O O O O
O., O O O O
Aksulu O O O O
H. O O O O
E. O O O O
Summary: O O O O
The O O O O
presence O O O O
of O O O O
weaknesses O O O O
in O O O O
the O O O O
efficacy O O O O
of O O O O
endogenous O O O O
natriuretic O O O O
and O O O O
vasodilator O O O O
agents O O O O
plays O O O O
a O O O O
significant O O O O
role O O O O
in O O O O
developing O O O O
high O O O O
blood O O O O
pressure. O O O O
It O O O O
is O O O O
often O O O O
suggested O O O O
that O O O O
oxidative O O O O
stress O O O O
is O O O O
critical O O O O
in O O O O
developing O O O O
hypertension O O O O
due O O O O
to O O O O
nitric O O O O
oxide O O O O
synthase O O O O
(NOS) O O O O
inhibition. O O O O
This O O O O
study O O O O
aimed O O O O
to O O O O
investigate O O O O
the O O O O
intrarenal O O O O
dopaminergic O O O O
system O O O O
activities, O O O O
involvement O O O O
of O O O O
oxidative O O O O
stress, O O O O
and O O O O
blood O O O O
pressure O O O O
changes O O O O
resulting O O O O
from O O O O
NOS O O O O
inhibition O O O O
with O O O O
N-nitro-L-arginine O O O O
(L-NNA) O O O O
and/or O O O O
L-buthionine O O O O
sulfoximine O O O O
(BSO). O O O O
Journal O O O O
More](http://www.bmrat.org/index.php/BMRAT/covid19) O O O O
Journal O O O O
Supplements O O O O
Conference O O O O
Abstracts O O O O
[Learn O O O O
More](http://www.bmrat.org/index.php/BMRAT/JournalSupplements) O O O O
Journal O O O O
Collections O O O O
Stem O O O O
Cells O O O O
and O O O O
Regenerative O O O O
Medicine O O O O
[Learn O O O O
More](http://www.bmrat.org/index.php/BMRAT/sct) O O O O
Special O O O O
Issues O O O O
Special O O O O
Issues O O O O
[Learn O O O O
More](http://www.bmrat.org/index.php/BMRAT/SpecialIssues) O O O O
Journal O O O O
Collections O O O O
Natural O O O O
Extract O O O O
[Learn O O O O
More](http://www.bmrat.org/index.php/BMRAT/extracts) O O O O
Publication O O O O
Awards O O O O
The O O O O
best O O O O
original O O O O
research O O O O
articles O O O O
[Learn O O O O
More](http://www.bmrat.org/index.php/BMRAT/awards) O O O O
Editors' O O O O
quote O O O O
Phuc O O O O
Van O O O O
Pham, O O O O
Editor-in-Chief O O O O
Affiliation O O O O
Why O O O O
publish O O O O
with O O O O
Biomedical O O O O
Research O O O O
and O O O O
Therapy O O O O
